ADJUVANTE SYSTEMISCHE THERAPIE BEIM MAMMAKARZINOM IN DEN NEUNZIGER JAHREN: STAND DER DINGE UND OFFENE FRAGEN

A. Goldhirsch; H. Neuenschwander; M. Castiglione; H. J. Senn; F. Cavalli

ADJUVANTE SYSTEMISCHE THERAPIE BEIM MAMMAKARZINOM IN DEN NEUNZIGER JAHREN: STAND DER DINGE UND OFFENE FRAGEN

Translated title of the contribution: Adjuvant systemic therapy of breast cancer in the 1990s: Present situation and open questions

A. Goldhirsch, H. Neuenschwander, M. Castiglione, H. J. Senn, F. Cavalli

Istituto Europeo di Oncologia

Research output: Contribution to journal › Article

Abstract

Adjuvant systemic therapy of breast cancer has been shown to reduce relapses and prolong survival in the women treated. This is true of all subpopulations studied. Six-month multidrug chemotherapy in premenopausal patients, and tamoxifen or shortterm chemotherapy in postmenopausal patients, are the treatments of choice in reducing the risk of relapse. In the near future ongoing research may answer some of the open questions surrounding the definition of populations for which the risk of relapse justifies therapy and the optimum manner of using available therapies. The modest but real improvement in prognosis of operable breast cancer was obtained solely by means of clinical trials. Participation in clinical research programs is becoming medically and socially mandatory.

Original language	German
Pages (from-to)	1771-1783
Number of pages	13
Journal	Schweizerische Medizinische Wochenschrift
Volume	120
Issue number	47
Publication status	Published - 1990

Fingerprint

ASJC Scopus subject areas

Medicine(all)

Cite this

Goldhirsch, A., Neuenschwander, H., Castiglione, M., Senn, H. J., & Cavalli, F. (1990). ADJUVANTE SYSTEMISCHE THERAPIE BEIM MAMMAKARZINOM IN DEN NEUNZIGER JAHREN: STAND DER DINGE UND OFFENE FRAGEN. Schweizerische Medizinische Wochenschrift, 120(47), 1771-1783.

@article{6d1b572efd4d4820affb19b77e6d7b21,

title = "ADJUVANTE SYSTEMISCHE THERAPIE BEIM MAMMAKARZINOM IN DEN NEUNZIGER JAHREN: STAND DER DINGE UND OFFENE FRAGEN",

abstract = "Adjuvant systemic therapy of breast cancer has been shown to reduce relapses and prolong survival in the women treated. This is true of all subpopulations studied. Six-month multidrug chemotherapy in premenopausal patients, and tamoxifen or shortterm chemotherapy in postmenopausal patients, are the treatments of choice in reducing the risk of relapse. In the near future ongoing research may answer some of the open questions surrounding the definition of populations for which the risk of relapse justifies therapy and the optimum manner of using available therapies. The modest but real improvement in prognosis of operable breast cancer was obtained solely by means of clinical trials. Participation in clinical research programs is becoming medically and socially mandatory.",

author = "A. Goldhirsch and H. Neuenschwander and M. Castiglione and Senn, {H. J.} and F. Cavalli",

year = "1990",

language = "Tedesco",

volume = "120",

pages = "1771--1783",

journal = "Schweizerische Medizinische Wochenschrift",

issn = "0036-7672",

publisher = "EMH Swiss Medical Publishers Ltd.",

number = "47",

}

TY - JOUR

T1 - ADJUVANTE SYSTEMISCHE THERAPIE BEIM MAMMAKARZINOM IN DEN NEUNZIGER JAHREN

T2 - STAND DER DINGE UND OFFENE FRAGEN

AU - Goldhirsch, A.

AU - Neuenschwander, H.

AU - Castiglione, M.

AU - Senn, H. J.

AU - Cavalli, F.

PY - 1990

Y1 - 1990

N2 - Adjuvant systemic therapy of breast cancer has been shown to reduce relapses and prolong survival in the women treated. This is true of all subpopulations studied. Six-month multidrug chemotherapy in premenopausal patients, and tamoxifen or shortterm chemotherapy in postmenopausal patients, are the treatments of choice in reducing the risk of relapse. In the near future ongoing research may answer some of the open questions surrounding the definition of populations for which the risk of relapse justifies therapy and the optimum manner of using available therapies. The modest but real improvement in prognosis of operable breast cancer was obtained solely by means of clinical trials. Participation in clinical research programs is becoming medically and socially mandatory.

AB - Adjuvant systemic therapy of breast cancer has been shown to reduce relapses and prolong survival in the women treated. This is true of all subpopulations studied. Six-month multidrug chemotherapy in premenopausal patients, and tamoxifen or shortterm chemotherapy in postmenopausal patients, are the treatments of choice in reducing the risk of relapse. In the near future ongoing research may answer some of the open questions surrounding the definition of populations for which the risk of relapse justifies therapy and the optimum manner of using available therapies. The modest but real improvement in prognosis of operable breast cancer was obtained solely by means of clinical trials. Participation in clinical research programs is becoming medically and socially mandatory.

UR - http://www.scopus.com/inward/record.url?scp=0025027849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025027849&partnerID=8YFLogxK

M3 - Articolo

C2 - 2255883

AN - SCOPUS:0025027849

VL - 120

SP - 1771

EP - 1783

JO - Schweizerische Medizinische Wochenschrift

JF - Schweizerische Medizinische Wochenschrift

SN - 0036-7672

IS - 47

ER -

ADJUVANTE SYSTEMISCHE THERAPIE BEIM MAMMAKARZINOM IN DEN NEUNZIGER JAHREN: STAND DER DINGE UND OFFENE FRAGEN

Abstract

Fingerprint

ASJC Scopus subject areas

Cite this

Access to Document